Adlai Nortye (ANL) Current Assets (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Current Assets of $26.9 million for Q4 2025, down 58.02% year-over-year from $64.1 million in Q4 2024, and down 58.93% quarter-over-quarter from $65.5 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Current Assets (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Current Assets for 4 consecutive years, with $26.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 58.02% year-over-year to $26.9 million; the TTM figure through Dec 2025 stood at $26.9 million (down 58.02% YoY), while the FY2025 annual figure was $26.9 million, down 58.02% from the prior year.
- Current Assets eased to $26.9 million in Q4 2025 per ANL's latest filing, from $65.5 million in the prior quarter.
- Across five years, Current Assets topped out at $101.2 million in Q4 2023 and bottomed at $26.9 million in Q4 2025.
- Historically, Current Assets has averaged $70.7 million across 4 years, with a median of $65.9 million in 2022.
- Annual changes were most pronounced in 2023 — Current Assets jumped 52.63% — and 2025, when it slumped 58.02%.
- Adlai Nortye's Current Assets stood at $66.3 million in 2022, then soared by 52.63% to $101.2 million in 2023, then slumped by 36.69% to $64.1 million in 2024, then plunged by 58.02% to $26.9 million in 2025.
- Business Quant data shows ANL's Current Assets at $26.9 million in Q4 2025, $65.5 million in Q2 2025, and $64.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 240.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 240.88 Mn |
| Dec 31, 2025 | 26.89 Mn |
| Jun 30, 2025 | 65.48 Mn |
| Dec 31, 2024 | 64.06 Mn |
| Jun 30, 2024 | 100.28 Mn |
| Dec 31, 2023 | 101.20 Mn |
| Dec 31, 2022 | 66.30 Mn |